Literature DB >> 15810893

Treatment of behavioural symptoms and dementia in Parkinson's disease.

Hasmet A Hanagasi1, Murat Emre.   

Abstract

Behavioural symptoms such as anxiety, depression and psychosis are common in Parkinson's disease (PD), and dementia occurs in about 90% of the patients. These symptoms can be more disabling than the motor dysfunction and they negatively impact quality of life, increase caregiver distress and are more frequently associated with nursing home placement. Depression can be treated with counselling and pharmacotherapy. Tricyclic antidepressants or selective serotonin reuptake inhibitors are widely used, but there is still need for controlled clinical trials. Management of psychosis in PD is complex and includes elimination of identifiable risk factors, reduction of polypharmacy and administration of atypical neuroleptics, which can alleviate psychotic symptoms without worsening motor functions. Clozapine is the best documented atypical neuroleptic shown to be effective against psychosis in PD patients. Cholinesterase inhibitors may prove additional benefit in psychotic PD patients. Recent evidence from small double-blind and open-label trials suggests that cholinesterase inhibitors may be effective in the treatment of dementia associated with PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810893     DOI: 10.1111/j.1472-8206.2005.00317.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

Review 1.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 2.  Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Authors:  Jack J Chen; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Reformulating psychological difficulties in people with Parkinson's disease: the potential of a social relational approach to disablism.

Authors:  Jane Simpson; Helen McMillan; Donna Reeve
Journal:  Parkinsons Dis       Date:  2013-08-13

4.  Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial.

Authors:  A Bogosian; C S Hurt; D Vasconcelos E Sa; J V Hindle; L McCracken; P Cubi-Molla
Journal:  Pilot Feasibility Stud       Date:  2017-01-16

5.  Prioritising target non-pharmacological interventions for research in Parkinson's disease: achieving consensus from key stakeholders.

Authors:  Angeliki Bogosian; Lorna Rixon; Catherine S Hurt
Journal:  Res Involv Engagem       Date:  2020-06-24

6.  Is Dementia in Parkinson' Disease Related to Chronic Stress, Anxiety, and Depression?

Authors:  Anita Pal; Nishi Pegwal; Madhuri Behari; Ratna Sharma
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

Review 7.  Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.

Authors:  Ruth Lamb; Jonathan D Rohrer; Andrew J Lees; Huw R Morris
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.